ArticleFrontiers in pharmacology2025

Case report: Durable response of immuno-chemotherapy targeting a rare ROS1 fusion-positive extensive-stage SCLC patient after primary resistance to crizotinib.

Mengli Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.